Evotec stock

EVT · Xetra · EUR

Compare Evotec
€2.51Change from previous close: −8.21%Absolute change: −€0.22

Close · November 20, 2026

Price history

−51.58% over the period

1 year: from €5.18 (November 20, 2025) to €2.51 (November 20, 2026), −51.58%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€2.51
October 30, 2026€2.82
September 30, 2026€3.10
August 31, 2026€3.25
July 31, 2026€3.41
June 30, 2026€5.00
May 29, 2026€5.28
April 30, 2026€5.24
March 31, 2026€4.29
February 27, 2026€5.88
January 30, 2026€6.22
December 30, 2025€5.45
November 28, 2025€5.80
November 20, 2025€5.18

At a glance

  • The company

    Develop and discover pharmaceutical products across oncology, autoimmune, cardiometabolic, CNS and rare diseases through R&D and biologics platforms

  • Latest results

    Quarter to September 30, 2026 · EPS -€0.15 (estimate -€0.47)

TickerLandia's take on Evotec

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€2.41
52-wk high€6.73

−62.76% from the 52-week high

Analysts · 8 analysts

Average target€3.75+49.64% vs. price

Buy 3 · Hold 5 · Sell 0 · Buy

TickerLandia Fingerprint: Evotec

Compared with similar companies: very low profitability, very low price, and very weak momentum.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Evotec is cheaper than similar companies

Evotec's Price/book: 0.69, −75% against the median of a group of 11 similar companies (2.83).

Compared with 11 similar companies

Evotec's metrics compared with similar companies
MetricEvotecPosition in the groupBand
Operating margin-18.0%Low
ROE-25.1%Low
Debt/equity0.75High
Price/book0.69Low
Net margin-25.2%Low

Grey band: the middle half of the group; tick: the median; dot: Evotec. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€164.93M

Latest quarter · Q3 2026

Net income

-€26.74M

Latest quarter · Q3 2026

Quarterly net margin

-16.2%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€445.3M
EPS
-€1.01
Volume
2.79M
Daily trading
€3.3M
Dividend yield
0.00%

How Evotec is changing

All results
  • Revenue grew 9.5% a year on average over the last 5 years

  • Operating margin fell from 2.8% to −8.4%

  • Shares outstanding up 14.6% in 5 years

Returns

Evotec returns

€1,000 invested in Evotec 5 years ago, on November 22, 2021, would be worth €59 today: −94.14% in total, −43.34% per year. This is the price return only: dividends are excluded.

PeriodEvotecDAX€1,000 becomes
1 month−7.94%−1.98%€921
6 months−48.86%+0.26%€511
Year to date−54.02%+1.28%€460
1 year−51.58%+6.55%€484
3 years−86.96%—€130
5 years−94.14%—€59
10 years−58.90%—€411

Over the last 6 months it has done better than 2% of the stocks in the Industrials sector.

Price only, without dividends. Calculate your investment

The chart in detail

Evotec: technical analysis

Evotec is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 97.3% below its all-time closing high (€91.95, March 3, 2000).

Trend
Downward
RSI (14 sessions)
32
Between 30 and 70
vs 200-session average
−39.34%

Active signals

  • Close below the low of the previous 20 sessions.

  • Trading on November 20, 2026 was 2.7 times the 20-session average.

Support and resistance

Price areas where Evotec has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€3.37+34.50%3 touches, last on November 9, 2026
  2. Resistance€3.13+25.02%4 touches, last on October 1, 2026
  3. Resistance€2.72+8.54%3 touches, last on November 3, 2026
  4. Last price€2.51
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved roughly in line with the DAX.

Beta (1 year) vs DAX
0.93
Volatility (60 sessions, annualised)
53.1%
Largest fall in the last year
−62.70%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Evotec: seasonality

Average monthly price change over 27 years

+4.7%Jan+3.0%Feb−2.3%Mar+3.7%Apr−0.6%May+1.7%Jun−2.6%Jul+3.1%Aug−2.2%Sep+3.0%Oct−0.7%Nov+0.3%Dec

Over the last 27 years, the strongest month for Evotec has been January: +4.72% on average, positive in 16 years out of 27. The weakest has been July: −2.63% on average, positive in 9 years out of 27. November, the current month, has been positive in 12 years out of 26 (−0.68% on average).

Show chart data
MonthAverageMedianPositive years
January+4.72%+5.47%16 of 27
February+2.97%−2.57%10 of 27
March−2.31%−2.29%12 of 27
April+3.70%−0.05%13 of 27
May−0.58%+0.75%14 of 27
June+1.75%−0.49%12 of 27
July−2.63%−3.04%9 of 27
August+3.08%−0.09%13 of 27
September−2.23%−2.97%11 of 27
October+2.98%+0.49%15 of 27
November−0.68%−0.19%12 of 26
December+0.32%−3.31%11 of 27

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Evotec and its competitors

With revenue of EUR 788.4 million in the fiscal year ended December 2025, down 1.1% from the previous year, and a net loss of EUR 103.5 million, Evotec SE employed 4,379 people. The company is headquartered in Hamburg, Germany, was founded in 1993, and changed its name from Evotec AG in April 2019.

Headquarters
Hamburg, Germany
Employees
4,379
Founded
1993
Chief executive
Christian Wojczewski
Evotec and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
EvotecEVT$489.39M-18.0%—−48.86%
PharmaNutraPHN$917.61M22.0%36.7−2.50%
Faes FarmaFAE$1.65B13.0%17.9+4.66%
FagronFAGR$1.97B14.3%19.5−0.20%
AlmirallALM$2.45B9.6%30.2−9.84%
Siegfried HoldingSFZN$3.4B16.7%16.7−19.46%

Same industry or related industries, similar size. Compare Evotec with its competitors · Full profile